# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
The NHS is expected to block the Alzheimer's drug donanemab due to safety risks and high costs following NICE's recent ...
The U.K.'s Medicines and Healthcare products Regulatory Agency approved Eisai and Biogen's Leqembi for treating mild co...
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (NASDAQ:BIIB, Corporate headquarters: ...
Needham analyst Ami Fadia reiterates Biogen (NASDAQ:BIIB) with a Buy and maintains $285 price target.
Mizuho analyst Salim Syed maintains Biogen (NASDAQ:BIIB) with a Outperform and lowers the price target from $277 to $251.
Truist Securities analyst Srikripa Devarakonda reiterates Biogen (NASDAQ:BIIB) with a Buy and lowers the price target from $...
Needham analyst Ami Fadia maintains Biogen (NASDAQ:BIIB) with a Buy and lowers the price target from $288 to $285.